November 03, 2022

COVID-19 Vaccine: Novavax Booster Authorized

On October 19, the FDA amended the Novavax COVID-19 Vaccine, Adjuvanted emergency use authorization to authorize the use of a first booster dose for patients 18 years and older:

Novavax has been authorized for the use of a first booster dose for patients 18 years and older:

On October 19, the FDA amended the Novavax COVID-19 Vaccine, Adjuvanted emergency use authorization to authorize the use of a first booster dose for patients 18 years and older:

  • For whom an FDA-authorized bivalent (updated) booster isn’t accessible or clinically appropriate
  • Who choose to get the Novavax booster because they wouldn’t otherwise get a COVID-19 booster

Use the new CPT code effective October 19, 2022:

Code 0044A for Novavax Covid-19 Vaccine, Adjuvanted - Administration - Booster Dose:

  • Long descriptor: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage; booster dose
  • Short descriptor: ADM SARSCOV2 5MCG/0.5ML BST

Visit the COVID-19 Vaccine Provider Toolkit for more information, and get the most current list of billing codes, payment allowances, and effective dates. Note: You may need to refresh your browser if you recently visited this webpage.